← Leaderboards
Glenn Dranoff
Dana-Farber Cancer Institute
$5,693,495
Attributed
$6,069,301
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $768K · FY2005–16$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$6,069,301 · 7
By mechanism
R01$5,103,349 · 4
P01$512,521 · 2
P30$453,431 · 1
Top collaborators
- David J Mooney2 shared
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- Margaret A Shipp$7,796,368
- Edward J Benz$50,055,526
- Steven J. Burakoff$9,993,867
Others in their field
Top investigators on “Neoplastic Cell”
- David Heimbrook · Leidos Biomedical Research, Inc.$139,710,838
- Gregory H Reaman · National Childhood Cancer Foundation$31,993,642
- Bruce W Stillman · Cold Spring Harbor Laboratory$25,455,900
- Ralph Parchment · Leidos Biomedical Research, Inc.$25,266,647
- Andrea Califano · Columbia University Health Sciences$22,374,316
- Wendell A Lim · University Of California, San Francisco$22,334,734
Research focus
Neoplastic CellMelanomaDendritic CellsT-LymphocyteImmuneImmune ResponseCellsTumorVaccinesCytotoxic T-Lymphocyte-Associated Protein 4Clinical TrialsMediatingTumor AntigensAntibodiesB-LymphocytesCancer PatientImmunotherapyCancer Immunology ScienceTumor ImmunityCd8b1 GeneCytokineAntigen PresentationBlocking AntibodiesLaboratory Mouse
Grant awards (26)
Cancer Immunology$93,190
P30 · FY2016 · CA · contact PI
Cancer Immunology$93,224
P30 · FY2015 · CA · contact PI
Biomaterial based breast cancer vaccine$366,115
R01 · FY2014 · EB
Targeting MFG-E8 as Melanoma Immunotherapy$306,522
R01 · FY2014 · CA · contact PI
Cancer Immunology$88,327
P30 · FY2014 · CA · contact PI
Biomaterial based breast cancer vaccine$385,497
R01 · FY2013 · EB
Targeting MFG-E8 as Melanoma Immunotherapy$297,042
R01 · FY2013 · CA · contact PI
Cancer Immunology$85,483
P30 · FY2013 · CA · contact PI
Targeting MFG-E8 as Melanoma Immunotherapy$316,002
R01 · FY2012 · CA · contact PI
Cancer Immunology$93,207
P30 · FY2012 · CA · contact PI
Targeting MFG-E8 as Melanoma Immunotherapy$316,002
R01 · FY2011 · CA · contact PI
Targeting MFG-E8 as Melanoma Immunotherapy$323,146
R01 · FY2010 · CA · contact PI
Targets of Immune-Mediated Tumor Destruction$293,631
R01 · FY2009 · CA · contact PI
Targets of Immune-Mediated Tumor Destruction$293,631
R01 · FY2008 · CA · contact PI
Targets of Immune-Mediated Tumor Destruction$293,631
R01 · FY2007 · CA · contact PI
Targets of Immune-Mediated Tumor Destruction$302,403
R01 · FY2006 · CA · contact PI
Targets of Immune-Mediated Tumor Destruction$309,680
R01 · FY2005 · CA
CSF Deficiency and Antitumor Immunity$235,124
R01 · FY2004 · CA
CSF Deficiency and Antitumor Immunity$235,124
R01 · FY2003 · CA
CSF Deficiency and Antitumor Immunity$235,265
R01 · FY2002 · CA
TUMOR VACCINES AND BONE MARROW TRANSPLANTATION$135,290
P01 · FY2002 · CA
NOVEL TARGETS FOR THE TREATMENT OF AML$0
P01 · FY2002 · CA
CSF DEFICIENCY AND ANTITUMOR IMMUNITY$301,659
R01 · FY2001 · CA
TUMOR VACCINES AND BONE MARROW TRANSPLANTATION$135,290
P01 · FY2001 · CA
CSF DEFICIENCY AND ANTITUMOR IMMUNITY$292,875
R01 · FY2000 · CA
TUMOR VACCINES AND BONE MARROW TRANSPLANTATION$241,941
P01 · FY2000 · CA